News & insights

CEPA was appointed by Unitaid to conduct a portfolio-level joint end-of-grant evaluation of its investments in Point of Care (POC) molecular diagnostics for HIV implemented by the Elizabeth Glaser Paediatric AIDS Foundation (EGPAF project) and CHAI-UNICEF (UCPOC project).  

The main evaluation objective was to consider at a portfolio level, the extent to which Unitaid’s HIV POC molecular diagnostics investments have contributed to increased access to innovative HIV diagnostics in resource-limited settings. The evaluation also encompassed an assessment of the impact of these investments and specific grant-level evaluations of each of the two individual grants. Strategic and operational recommendations were developed based on the evaluation findings.  

The evaluation framework was structured along four pillars reflective of the scope of the evaluation: (i) grant design and implementation; (ii) access barriers including around issues such as demand and adoption at the country and global level, availability and affordability of new products, commodity market dynamics and the introduction of new products etc; (iii) sustainability and scalability including health financing; and (iv) impact assessment.  

The methodology employed was a theory of change-based approach with mixed methods comprising document review, stakeholder interviews across a range of global and country level stakeholders, country case studies (Cameroon, Lesotho, Kenya, Uganda, Zimbabwe and Mozambique), impact modelling, and data and quantitative analysis.

The evaluation report can be found here.